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Summary
Purpose. Laboratory evidence indicates that tumor growth depends on the balance between cell proliferation and
cell death, and many anticancer agents may exert their therapeutic eﬀect by decreasing proliferation and increasing
apoptosis. Additionally, clinical observations indicate that overexpression of HER-2 or topoisomerase IIa (topo
IIa) may be predictors of better response to anthracyclines in breast cancer. The objective of this study was to
determine if proliferation (Ki-67), apoptosis (TUNEL), and expression of HER-2 and topo IIa are aﬀected by
anthracycline treatment, and if these molecular markers predict anthracycline responsiveness.
Experimental design. Thirty-three women with primary breast tumors ‡3 cm received either doxorubicin (75 mg/
m2) or epirubicin (120 mg/m2) for 4 cycles before surgery. Clinical response was evaluated after 4 cycles of treat-
ment. Changes in molecular markers were assessed from core needle biopsy taken before treatment (D0), at 24–48 h
(Dl) and on day 7 (D7) while on treatment, and from the surgical specimen excised on day 84 (D84) after the fourth
cycle of chemotherapy.
Results. The overall clinical response rate was 51% (17 of 33 patients), with a 12% complete clinical response rate
(4 of 33 patients). There were trends for tumors with higher apoptosis and topo IIa at baseline (D0) to be more
responsive to anthracyclines, p = 0.1 and p = 0.08, respectively. Median apoptosis increased from D0 to Dl
(p = 0.06) while median Ki-67 decreased (p = 0.07). Overall, expression of HER-2 remained stable throughout the
chemotherapy administration. By Day 84, topo IIa had signiﬁcantly decreased from baseline in responders, while it
increased in non-responders, p = 0.03.
Conclusions. In human primary breast cancer, anthracycline treatment causes an early increase in apoptosis and a
decrease in proliferation. In this pilot study, higher apoptosis and topo IIaa levels in primary tumors were asso-
ciated with greater responsiveness to anthracyclines, and topo IIa levels declined in responsive tumors.
Introduction
Systemic chemotherapy and endocrine treatment for
operable breast cancer signiﬁcantly decreases the risk of
relapse and death [1]. Systemic treatment before surgery
(neoadjuvant therapy) has a number of theoretical
advantages in breast cancer and can increase rates of
breast conservation [2]. A decrease in the size of the
primary tumor, indicating response to therapy, can be
used as a surrogate marker of treatment eﬃcacy on
systemic micrometastases. Moreover, access to the pri-
mary tumor aﬀords the opportunity for in vivo sensi-
tivity testing and for obtaining tissue to study the
mechanism of action of a therapy and molecular chan-
ges that might predict response. At present, it is not
possible to identify at the outset those patients who are
more likely to respond to a particular chemotherapy, or
to determine which type of chemotherapy would be
most eﬀective in an individual patient. Established
prognostic factors such as tumor size and nodal
involvement are important indicators of the probability
of micrometastatic spread and thus of breast cancer
relapse and survival, but have not been predictive of
sensitivity to treatment. Estrogen receptor and proges-
terone receptor expression are established predictive
factors for endocrine therapy [3], but predictive markers
for chemosensitivity are less well deﬁned.
Anticancer agents may exert their therapeutic eﬀect
by decreasing proliferation, increasing apoptosis, or
both. In breast cancers, chemotherapy has been found
to induce apoptosis within 24 h of treatment [4]. Simi-
larly, some studies have examined changes in tumor
proliferation during treatment and found a decrease
after some types of cytotoxic therapies [5–10] . While
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proliferation and apoptosis are relatively global assess-
ments of cellular conditions and response, certain types
of chemotherapy may target speciﬁc individual mole-
cules that regulate these processes. Several clinical
reports have suggested that breast cancer patients with
tumors that overexpress HER-2 may derive more beneﬁt
from anthracycline-based therapy, suggesting that this
molecule or pathway may be a target for this type of
chemotherapy [11,12]. However, clinical studies have
not been consistent, with one report linking HER-2
expression with resistance to chemotherapy [13].
Attempts to link HER-2 up-regulation to increased
anthracycline sensitivity via manipulating expression in
cell lines have also been inconsistent [14,15]. Topo-
isomerase IIa (topo IIa), a known molecular target for
anthracyclines in experimental systems [16], is frequently
co-ampliﬁed with HER-2 in breast cancer – the prox-
imity of the topo IIa and HER-2 genes on chromosome
17 provides a plausible, although unproven, mechanism
for the putative link between HER-2 overexpression and
anthracycline response [17].
The status of biological markers before treatment,
together with changes as a result of treatment, may
allow early prediction of sensitivity or resistance to
neoadjuvant therapy and provide a window for under-
standing the mechanism of action of therapies. To ex-
plore these ideas, we have now measured apoptosis,
proliferation (Ki-67), and HER-2 and topo IIa expres-
sion in core needle biopsy specimens from primary
breast cancers obtained before, during, and after single
agent anthracycline chemotherapy. The study design
allowed investigation of the speciﬁc eﬀect of anthracy-
cline chemotherapy in isolation. We hypothesized that
anthracycline chemotherapy would result in a decrease
in proliferation and an increase in apoptosis. Addi-
tionally, tumors with higher HER-2 or topo IIa levels
were expected to have increased sensitivity to anthra-
cyclines.
Methods
Patient population
Patients with the following criteria were considered eli-
gible for the present study: (1) histologically conﬁrmed
invasive breast cancer; (2) initial diagnosis and biopsy
within 6 weeks of study entry; (3) clinical tumor size ‡
3 cm at diagnosis; (4) adequate renal and hepatic func-
tion; and, (5) signed and approved informed consent.
Exclusion criteria for the study were: (1) prior systemic
therapy; (2) prior radiation therapy; (3) signiﬁcant his-
tory of heart disease, serious illness, or infection; and,
(4) inﬂammatory breast cancer.
From November 1996 to June 2000, 34 women were
considered eligible and thus included for this molecular
marker study that had been approved by the Institu-
tional Review Boards (IRB) of the Lagomaggiore
Hospital, Mendoza, Argentina. Of these, one was later
excluded from the study because she had an inﬂamma-
tory breast cancer without a deﬁned tumor mass.
Written informed consent was obtained from the
remaining 33 eligible patients. Patients received doxo-
rubicin 75 mg/m2 or epirubicin 120 mg/m2 for 4 cycles
every 3 weeks before surgery. Patients received 6 cycles
of CMF postoperatively, and adjuvant hormonal ther-
apy after surgery according to the investigators’ judg-
ment based on estrogen and progesterone receptor
analysis. Women who had breast-conserving surgery
were given postoperative radiotherapy to the breast.
Staging and response
Clinical staging and size of the primary tumor were
recorded by two clinicians following WHO guidelines at
the start of treatment, at each cycle, and after comple-
tion of four cycles of neoadjuvant chemotherapy.
Response was deﬁned according to the following crite-
ria: complete response (CR) was deﬁned as no residual
palpable disease, partial response (PR) as greater than
50% reduction in bi-dimensional measurements, stable
disease (SD) as less than 50% reduction or 25% increase
in tumor size, and progressive disease (PD) as greater
than 25% in crease in tumor size. Tumor overall
response (OR) was deﬁned as CR or PR, and non-
response as SD or PD.
Timing and collection of samples
For most patients, core needle biopsies of the primary
breast tumors were performed using a 14-gauge spring-
loaded needle (C.R. Bard, Inc., Covington, GA). One to
three cores, 1 mm in diameter and 3–10 mm in length,
were generally obtained. On some initial patients, a
smaller gauge needle was used; when inadequate
amounts of cells were noted in some specimens, inves-
tigators were advised to use 14-gauge needles for sub-
sequent patients. Needle biopsy material and tissue from
surgery were immediately ﬁxed in 10% buﬀered forma-
lin.
Molecular markers were assessed from biopsies
obtained before treatment (Day 0), at 24–48 h (Day 1),
on day 7 (Day 7), and at surgical excision (Day 84, after
4 cycles of chemotherapy). Timing at either 24 or 48 h
was based on availability of the patients for repeat
biopsies. For day 0 samples, 2 patients had only DCIS
and 6 had missing blocks, and these were excluded from
further analyses. In addition, 8 had relatively small
number of tumor cells and therefore only certain bio-
markers could be evaluated and compared with samples
at other time points. For day 1 samples, one had DCIS
only, 11 had no tumor, 5 had very few tumor cells, and
16 were of good quality. For day 7 samples, 3 had
missing blocks, one had DCIS only, 8 had no tumor
cells, 7 had very few tumor cells, and 14 were of good
quality. At day 84, 26 cases had residual invasive tumor
cells for biomarker evaluation, including 4 cases with
relatively few tumor cells on H and E examination, and
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these were not used for biolmarker evaluation; there-
fore, 22 cases were unavailable for staining on Day 22.
Immunohistochernical (IHC) scoring (by SKM and
DCA) was performed in a blinded fashion without any
knowledge of the patients’ clinical data, Since some
specimens were too small, or of inadequate cellularity to
be analyzed by IHC, data is not available at all time
points for some patients.
Topo IIa analysis was not included in the initial
study design but was added later, after the molecular
and clinical ﬁndings of a possible role of this protein in
the anthracycline sensitivity became apparent. Because
of limitations of tissue availability and because tissue
from some cores had been exhausted from previous
study, only specimens from pretreatment and Day 84
could be evaluated for this marker on tissue that
remained.
Immunohistochemical analysis for the biomarkers
Immunohistochemistry (IHC) was performed on 4-lm
thick sections after deparaﬃnization. The information
on primary antibodies is summarized in Table 1. All
IHC analyses except HER-2 required antigen retrieval in
a pressure-cooker for 5 min using Tris–HC1 buﬀer at
pH 9.0. Endogenous peroxidase was blocked with 3%
hydrogen peroxide and non-speciﬁc staining with avi-
din–biotin block (Vector Labs, CA). Sections were then
incubated with primary antibody for 60 min at room
temperature, followed by secondary antibody at 1:200
dilution for 30 min. Labeled streptavidin–horseradish
peroxidase (DakoCytomation, CA) at 1:200 dilution
was applied next, and the IHC reaction was developed
with DAB+ (DakoCytomation, CA) for 15 min and
enhanced with 0.2% osmium tetroxide for 30 s. Sections
were counterstained with light methyl green and cov-
erslipped.
For TUNEL assay, after antigen retrieval, sections
were treated with TdT buﬀer for 5 min and then incu-
bated with TdT-d-UTP biotin 16 (Roche Diagnostics,
Switzerland) for 2 h and 15 min at 37 C. The remain-
der of the procedure was identical to other markers.
Interpretation of IHC staining
For HER-2, IHC stained slides were scored using ‘Allred
score’ with a range of 0–8 and a cut-oﬀ of ‡3, corre-
sponding to 10% cells with complete membrane staining,
as previously validated [18]. For Ki67 (MIB-1), topo IIa,
and TUNEL, 200–500 cells were point-counted under
the microscope and results were recorded as percent
positive. For MIB-1 a cut-oﬀ of 20% was used as de-
scribed before to deﬁne low versus high proliferation rate
[19,20]. Since no validated cut-oﬀs exist for topo IIa or
TUNEL, the median scores in this patient cohort were
used as the cut-oﬀ to deﬁne low versus high values
(Table 1).
Statistical methods
Baseline apoptosis, Ki-67, HER-2, and topo IIa were
analyzed as possible predictors of response by the Wil-
coxon rank-sum test. Sequential measurements of
change in apoptosis (%) and in expression of Ki-67 (%)
and HER-2 (IHC score) at Day 1, Day 7, and Day 84
were calculated by comparing with the pretreatment
levels (change equals posttreatment minus pretreatment
scores) using the Wilcoxon signed-rank test. Changes in
topo IIa expression were calculated by comparing DO
versus D84. The changes in marker levels between
responders and non-responders were then considered as
predictors of response based on the Wilcoxon rank-sum
test.
Results
Table 2 describes the clinical and tumor characteristics.
The median age of patients enrolled in this study was
50 years (range 32–69 years), and 51% of women were
postmenopausal. The median tumor size was 6 cm
(range 3–9 cm) and, not unexpectedly, 70% (21) of the
study population had clinical lymph node involvement
at the time of diagnosis.
After 4 cycles of anthracycline chemotherapy at
about 3 months the clinical overall objective response
rate was 51% (17 of 33) which is in an expected range,
with median tumor size of 6 cm. The majority of
patients (64%) had a lumpectomy plus axillary node
dissection as their surgical procedure, and 88% of
residual tumors were invasive ductal carcinomas.
Based on cut-oﬀs for molecular assessments deﬁned
in Table 1, at baseline 65% (13/20) of tumors had high
proliferation rate (Ki-67 > 20%), 25% (6/24) overex-
pressed HER-2, 63% (10/16) had high levels of topo IIa,
and 55% (12/22) had a high apoptosis rate. Possibly
because of small numbers in the analysis, none of the
tumor markers at baseline were found to be statistically
signiﬁcant predictors of chemotherapy response
Table 1. Details of the immunohistochemical assays for the molecular markers
Marker Antibody clone Dilution of primary antibody Source Scoring Cut-oﬀ
Ki-67 MIB-1 1:200 DakoCytomation % 20%
HER-2 Tab 250 1:200 Zymed Allred score ‡3 (>10%)
Topo IIa 3F6 1:100 Novocastra % 5%
TUNEL – 1:400 Roche Diagnostics % 0.4%
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(Table 3); however, there was a trend for tumors with
higher levels of topo IIa to respond to anthracycline
chemotherapy, median topo IIa = 17% versus 3.5% in
responders versus non-responders, respectively, p =
0.08. There was also a trend for tumors with higher
apoptosis to be more responsive – median apoptosis was
0.9% in responders versus 0.2% in non-responders, p =
0.1. Two of 13 responders were HER-2 positive, versus 2
of 11 of the non-responders.
Serial biopsies allowed for monitoring changes over
time in median Ki-67, apoptosis, HER-2, and topo IIa.
Median changes in molecular markers compared to
baseline are summarized in Table 4. As expected,
decreases in proliferation were noted early, within
24–48 h after administration of anthracycline chemo-
therapy. By day 1 proliferation tended to decrease
(median n = )1.0%, p = 0.07) and apoptosis to in-
crease (median n = +0.65%, p = 0.06) in response to
chemotherapy. These observations were maintained
over time although none achieved statistical signiﬁcance.
HER-2 remained unchanged.
Topo IIa levels were only available on Day 0 and 84.
Overall, topo IIa showed only a small insigniﬁcant de-
crease during this time. However, in patients responding
to chemotherapy, the staining for topo IIa decreased
from pretreatment to Day 84 (median n = )9.5%),
while in patients not responding to chemotherapy, topo
IIa staining increased (median n = +4.5%, p = 0.03)
(Table 5). None of the changes in the other markers in
the study (apoptosis, proliferation, and HER-2 status)
were signiﬁcantly diﬀerent between responders and non-
responders (Table 5).
Discussion
The results of the present study indicate that in human
breast cancer, treatment with anthracycline chemother-
apy causes a very early increase in apoptosis and de-
crease in proliferation. Higher apoptosis in the primary
tumor is associated with tumor responsiveness and may
indicate a lower threshold for chemotherapy-triggered
Table 2. Clinical and tumor characteristics of locally advanced breast
cancer patients who received single agent anthracycline-based neoad-
juvant chemotherapy
% n
Age
Median 50 yrs
Range 32–69 yrs
Menopausal status
Premenopausal 49% (16)
Postmenopausal 51% (17)
Tumor size
Median 6 cm
Range 3–9 cm
Clinical Nodal statust
Node-negative 30% (12)
Node-positive 70% (21)
Clinical response
(WHO classiﬁcation)
Complete response (CR) 12% (4)
Partial response (PR) 39% (13)
Stable disease (SD) 49% (16)
Progressive disease (PD) 0% (0)
Overall response rate
(CR + PR)
51% (17)
Type of Surgery
Lumpectomy 64% (21)
Modiﬁed radical mastectomy 36% (12)
Histology in initial
core biopsy
Inﬁltrating ductal carcinoma 91% (30)
Inﬁltrating lobular carcinoma 9% (3)
Table 3. Predictive value of biomarkers at baseline
Marker Responders Non-responders
N Median (% or IHC score) N Median (% or IHC score)
p-value
Ki-67 (%) 11 21.0 9 23.0 0.8
Apoptosis (%) 11 0.9 11 0.2 0.1
HER-2 (IHC score) 13 0 11 0 0.7
Topo IIa (%) 8 17 8 3.5 0.08
Table 4. Median changes over time in levels ofKi67, apoptosis, HER-2,
and Topo IIa induced by anthracyclines therapy
d Day 1
median
d Day 7
median
d Day 84
median
Ki-67 (%) )1(n = 14)* )7 (n = 13) )6.5 (n = 18)
Apoptosis (%) +0.6 (n = 13)** +0.1 (n = 13) +0.2 (n = 20)
HER-2
(IHC score)
0 (n = 12) 0 (n = 17) 0 (n = 22)
Topo IIa (%) ND ND )1.5 (n = 16)
d Day 1: Diﬀerence between Day 1 value and Day 0 value; d Day 7:
Diﬀerence between Day 7 value and Day 0 value;nDay 84: Diﬀerence
between Day 84 value and Day 0 value.
ND: not done.
*p = 0.07; **p = 0.06.
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cell death. In addition, tumors and cells with high topo
IIa levels may be selectively sensitive to anthracyclines.
This study had a number of unique aspects, providing
complementary data to laboratory results. The trial was
designed to study the speciﬁc eﬀects and mechanisms of a
single chemotherapeutic agent. Most prior clinical stud-
ies used combination chemotherapy, making it impossi-
ble to focus on the eﬀect of a particular agent. Also,
testing was done on intact human breast tissue, with
vasculature, stroma, and other components, conditions
that cannot be replicated in laboratory experiments.
The balance between programmed cell death (apop-
tosis) and cell proliferation determines tumor growth,
and any, alteration between the two factors is a key ele-
ment for the uncontrolled expansion of malignant tu-
mors [21,22]. Laboratory studies with cell lines indicate
that many anticancer agents act by inducing apoptosis,
and failure of induction of apoptosis in vitro by chemo-
therapeutic agents is a mechanism of chemoresistance
and has been used for testing the eﬃcacy of speciﬁc or
novel therapies [23,24]. The central biochemical event of
apoptosis is endonucleolysis, which results in DNA
cleavage into oligonucleosome-sized fragments [25].
These fragments form the basis of TUNEL assay, which
has been a reproducible method to assess programmed
cell death in clinical samples [26] . In the current study,
apoptosis mainly increased in the ﬁrst 24–48 h after
treatment, corroborating laboratory ﬁndings of early
induction of apoptosis within few hours [27]. A previous
neoadjuvant study has reported that an increase in
apoptosis in the ﬁrst 24 h of treatment is a signiﬁcant
predictor of tumor response to two diﬀerent well known
chemotherapeutic agents: mitoxantrone and methotrex-
ate [28]. Another study showed the same ﬁndings fol-
lowing treatment with tamoxifen [29], thus suggesting
that the predictive value of apoptosis is probably not
restricted to speciﬁc drugs but rather is valid for many
drugs with diﬀerent mechanisms of action.
Changes in proliferation have also been correlated
with treatment in several studies [5–10]. For instance, a
decrease in Ki-67, a speciﬁc nuclear antigen expressed
only on proliferating cells (late G1-, S-, and G2-phases
of the cell cycle) [30], has been found to be a signiﬁcant
predictor of objective response to chemotherapy [31], In
the present report, overall proliferation, as measured by
Ki-67, tended to decrease by the ﬁrst 24–48 h after
treatment.
With regard to HER-2, contrasting results have been
reported on its predictive role in anthracycline-treated
patients. Some large studies have reported a positive
association between HER-2 overexpression and favor-
able response to anthracyclines in breast cancer
[11,12,32]. However, the existence of that association
and its underlying mechanism remain controversial [33].
In the present report, HER-2 overexpression did not
predict a favorable (or unfavorable) response to anth-
racyclines. Furthermore, HER-2 status did not change
during the course of therapy, suggesting that the HER-2
protein is not a target for anthracyclines.
Finally, this data supports the idea that rather than
HER-2, topo IIa is actually an important therapeutic
target of anthracyclines, and that levels of topo IIa are
important determinants of sensitivity of breast cancer to
anthracycline-based therapy. Since topo IIa is a known
target of anthracyclines in experimental models, tumors
with higher levels or a higher proportion of cells with
increased expression should be more sensitive and
respond better to the drug. Cells within the tumor that
preferentially express topo IIa may be selectively killed
by drug exposure, thus accounting for the observation
of falling levels associated with sensitivity. Some other
studies also indicate that topo IIa overexpression, as
well as gene ampliﬁcation, are important determinants
of sensitivity of breast cancer to anthracyclines, [34]
though ﬁndings have not always been consistent [35,36].
Part of this disparity may be methodological, and the
optimal assay for topo. IIa has not been validated.
This was a pilot study, which began in 1996. The
study has a number of limitations; one of which is the
relatively small number of patients that could be
recruited at a single site, despite a 4-year eﬀort.
Expanding such studies to multiple centers could be
useful, especially as the use of neoadjuvant therapy in
operable breast cancer becomes more widely accepted in
the clinic. In earlier stages of the study, some specimens
were too small or of inadequate cellularity for analysis,
further reducing the power to detect biologically,
meaningful diﬀerences. Careful attention to technique,
experience, and the use of a fully automated, 14-gauge
spring-loaded biopsy needle can improve cellular ade-
quacy. Also, in other, later studies, we have found that
cellular adequacy can be substantially improved if 6
cores are obtained rather than only 1 or 2, as was done
for most patients in the present study. IHC-based
assessment of markers limited the number of markers
that could be examined, and all specimens were pre-
served in formalin and paraﬃn. In the future, ﬂash
freezing of tissue and applying high through-put
molecular techniques will allow analysis of thousands of
Table 5. Median changes over time in levels of Ki-67, HER-2, apop-
tosis, and Topo IIa according to clinical response
Marker Responders Non-
Responders
N Median N Median
Ki-67 (%) D Day 1 7 )5 7 )1
D Day 7 5 6.8 8 )12.0
D Day 84 10 )6.5 8 )2.5
HER-2 D Day 1 5 0 7 0
D Day 7 7 0 10 0
D Day 84 12 0 10 0
Apoptosis (%) D Day 1 6 0.85 7 0.6
D Day 7 5 0.7 8 0.35
D Day 84 10 0.25 10 0.3
Topo IIa (%)* D Day 84 8 )9.5 8 4.45
*p = 0.03.
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genes and proteins simultaneously, rather than just a
few by IHC.
In conclusion, this small prospective clinical study
supports the idea that neoadjuvant chemotherapy pro-
vides a platform from which to discover predictive
markers of chemotherapy response. Because the tumor
is accessible for initial and serial biopsies, assessment of
molecular markers before and after treatment is feasible
and should become widely applied to explore the
mechanism of action of novel agents and to identify
molecular proﬁles of changes that would predict re-
sponse. From molecular mechanisms, pathways of sen-
sitivity or resistance can be understood, and therapies
can be rationally optimized and more rapidly improved.
Furthermore, molecular markers could be used to select
the optimal chemotherapeutic agent, thus sparing pa-
tients the side eﬀects and morbidity of ineﬀective, or less
eﬀective, treatment.
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